Union européenne - estonien - EMA (European Medicines Agency)

mylan s.a.s. - pregabaliin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - epilepsypregabalin mylan pharma on näidustatud adjunctive ravi täiskasvanutel, osaline krambid koos või ilma sekundaarse üldistada. generaliseerunud Ärevus disorderpregabalin mylan pharma on näidustatud ravi generaliseerunud Ärevushäire (gad) täiskasvanutel.

Estonie - estonien - Ravimiamet

teva pharma b.v. - erlotiniib - õhukese polümeerikattega tablett - 150mg 1tk 30tk

Estonie - estonien - Ravimiamet

teva pharma b.v. - dutasteriid - pehmekapsel - 0,5mg 90tk; 0,5mg 10tk; 0,5mg 30tk; 0,5mg 60tk; 0,5mg 50tk; 0,5mg 28tk

Estonie - estonien - Ravimiamet

teva pharma b.v. - dutasteriid - pehmekapsel - 0,5mg 50tk; 0,5mg 90tk; 0,5mg 60tk; 0,5mg 28tk; 0,5mg 100tk

Estonie - estonien - Ravimiamet

teva pharma b.v. - erlotiniib - õhukese polümeerikattega tablett - 100mg 1tk 30tk

Estonie - estonien - Ravimiamet

g.l. pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 10tk; 20mg 14tk; 20mg 45tk; 20mg 28tk; 20mg 90tk; 20mg 98tk

Estonie - estonien - Ravimiamet

g.l. pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 45tk; 10mg 30tk; 10mg 90tk; 10mg 100tk; 10mg 5tk; 10mg 42tk; 10mg 60tk; 10mg 10tk

Estonie - estonien - Ravimiamet

g.l. pharma gmbh - rivaroksabaan - õhukese polümeerikattega tablett - 15mg 30tk; 15mg 45tk; 15mg 10tk; 15mg 42tk; 15mg 14tk; 15mg 5tk; 15mg 90tk; 15mg 60tk; 15mg 100tk

Union européenne - estonien - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Estonie - estonien - Ravimiamet

woerwag pharma gmbh & co. kg - sitagliptiin - õhukese polümeerikattega tablett - 25mg 14tk; 25mg 100tk; 25mg 10tk; 25mg 30tk; 25mg 28tk; 25mg 98tk